- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 24.02. | Pfizer sets sights on Summit's bispecific in combo with its ADCs | ||
| 24.02. | EC authorises Celltrion's Avtozma for multiple indications | ||
| 24.02. | Transforming manufacturing and packaging at PHARMAP 2025 | ||
| 24.02. | Semaglutide shortage ends as FDA sets deadline for compounders | ||
| 24.02. | MeiraGTx seeks UK approval after gene therapy restores sight in children born blind | ||
| 24.02. | Teva and Alvotech launch ustekinumab biosimilar injection in US | ||
| 24.02. | FDA approves Mirum's Ctexli for cerebrotendinous xanthomatosis | ||
| 21.02. | Struggling bluebird bio to go private for less than $30m | ||
| 21.02. | Pfizer shelves haemophilia gene therapy Beqvez amid low demand | ||
| 21.02. | UroGen acquires IconOVir's oncolytic virus assets | ||
| 21.02. | GLP-1 receptor agonists could hold promise for opioid use disorder treatment | ||
| 21.02. | How CNS researchers are handling clinical trial turbulence | ||
| 21.02. | NICE green lights two blood cancer therapies for NHS use | ||
| 21.02. | Incyte and Genesis collaborate on small-molecule medicines | ||
| 21.02. | Navigating the Complexities of Sustainable Specialty Pharma Supply Chains | ||
| 21.02. | Japan's MHLW approves CSL Behring's Andembry to stop HAE attacks | ||
| 20.02. | Zealand Pharma steadfastly upholds amylin-based obesity drug strategy | ||
| 20.02. | X4 and taiba to distribute WHIM syndrome therapy in Middle East | ||
| 20.02. | Key pharma launch trends in 2024 | ||
| 20.02. | WHO targets over half a million children in Gaza for polio vaccine drive | ||
| 20.02. | FDA authorises ImmunityBio's BCG alternative to treat bladder cancer | ||
| 20.02. | Pharma and medtech industry reacts to FDA, CDC and NIH job cuts | ||
| 20.02. | FDA grants priority review for Boehringer's zongertinib NDA in NSCLC | ||
| 19.02. | Scientists develop largest ever biological AI model that 'thinks in nucleotides' | ||
| 19.02. | Supernus's stock sinks after depression drug fails trial |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
